Cell and Gene Therapy Market Dynamics by Disease Type: Development, Trends, and Forecasts, 4th Edition (2024-2030)

22 Apr 2025

Categories:

The Cell and Gene Therapy Market Dynamics by Disease Type: Development, Trends, and Forecasts, 4^th Edition (2024-2030) report by Kalorama Information explores the transformative potential of cell and gene therapies in modern medicine. These therapies offer groundbreaking treatments by addressing genetic causes of diseases and modulating the immune system. The report highlights the surge in new therapies and a promising pipeline, with significant clinical trial activity across various therapeutic areas, including oncology and cardiology.

This comprehensive report segments the market by therapeutic areas, providing detailed market estimates, forecasts, and insights into the competitive landscape. It covers global developments in cell, gene, and RNA therapy markets, focusing on key products, research trends, market breakdowns, regional revenues, and competitor analysis.

Key therapeutic areas covered include:

Oncology
Neurology
Musculoskeletal
Dermatology
Cardiology/Non-oncology blood
Other

The report excludes RNA therapies for COVID-19 and mRNA vaccines for infectious diseases, focusing instead on broader gene therapy applications. It also omits cord blood products, considering their classification as transplants.

Methodologically, the report combines primary and secondary research, including interviews with industry participants and comprehensive literature reviews. It provides market highlights, forecasts, and competitive analyses, discussing market indicators, trends, and barriers. Given the nascent stage of gene therapies, forecasts are based on limited precedents, with market size estimates provided for 2024 and projections through 2030.

This report serves as a crucial resource for understanding the evolving landscape of cell and gene therapies, offering valuable insights for stakeholders in the healthcare and biotechnology sectors.

Cell and Gene Therapy Market Dynamics by Disease Type: Development, Trends, and Forecasts, 4th Edition (2024-2030) is also the companion to another 2025 Kalorama Information report, Cell and Gene Therapy Market Deals: Investment, M&A, and Partnerships, 2021-2025 (3rd Edition) , which provides an unparalleled deep dive into the CGT market’s financial ecosystem, covers financing, funding, partnering, M&A, tech transfers, IPOs/SPACs, and other deals.

Table of Contents

Chapter 1: Executive Summary
- Overview
- Scope and Methodology
- Market Overview and Potential
Chapter 2: Introduction to Cell and Gene Therapy
- Introduction
- Cell Therapy
  - CAR T
  - Stem Cells
  - Adult Stem Cells
  - Human Embryonic Stem Cells
- Gene Therapy
  - Viral Vector System and New Developments
  - Non-viral Systems for Transporting Genes
  - Gene Editing
- Cell and Gene Therapy: Characteristics
- Staffing
- Manufacturing Process for CAR-T
  - Leukapheresis
  - Activation
  - Transduction
  - Expansion
- Cell and Gene Therapy Manufacturing Processes
- Cost
- Reimbursement
- Logistics
- Mergers and Acquisitions
- Deals, Agreements, and Collaborations
- Regulatory Developments
  - Fast Track
  - Orphan Drug
  - Breakthrough Therapy
  - Accelerated Approval
  - Priority Review
  - Gene Therapy Approval Process
- Pipeline, Development Overview
- Pipeline, Development Progress
- Pipeline by Condition and Therapeutic Area
- Phase III Development
- End Users
  - Wound Care Centers
  - Cancer Centers
Chapter 3: Cell and Gene Therapy Markets in Oncology
- Overview
  - Biochemistry of Cancer Cells
- Causes of Cancer Growth
  - Environmental Factors, DNA, RNA
  - Cellular Oncogenes
  - Tumor Suppressor Genes
- Global Cancer Burden
- Market Outlook
- Principal Products
  - Abecma
  - APCeden
  - Aucatzyl
  - Breyanzi
  - Carvykti
  - CreaVax-RCC
  - Delytact
  - Gendicine
  - Imlygic
  - Immuncell-LC
  - Kymriah
  - Provenge
  - Relma-cel
  - Rytelo
  - Tecartus
  - Tecelra
  - Yescarta
  - Zevor-cel
- Trends in Research and Development
  - Phase III Development
- Market Breakdown of Cell and Gene Therapies
  - Oncology Cell and Gene Therapy Market by Cancer Type
- Regional Market Summary
- Competitor Summary
Chapter 4: Cell and Gene Therapy Markets in Neurological-Related Disorders
- Overview
- Market Outlook
- Principal Products
  - Amvuttra
  - Libmeldy/ Lenmeldy
  - NeuroNata-R
  - Onpattro
  - SKYSONA
  - Spinraza
  - Stemirac
  - Upstaza
  - Wainua
  - Zolgensma
- Trends in Research and Development
  - Phase III Development
- Market Breakdown of Cell and Gene Therapies
- Regional Market Summary
- Competitor Summary
Chapter 5: Cell and Gene Therapy Markets in Musculoskeletal Conditions and Disorders
- Overview
- Market Outlook
- Principal Products
  - AlloStem
  - Amondys
  - BIO4
  - Carticel
  - Cartiform
  - CartiLife
  - Cartistem
  - Chondron
  - Elevidys
  - Exondys
  - JACC
  - MACI
  - Ortho-ACI and Ortho-ATI
  - Ossron
  - Osteocel and Osteoplus
  - Spherox
  - Trinity Elite and Trinity Evolution
  - Vyondys
- Trends in Research and Development
  - Phase III Development
- Market Breakdown of Cell and Gene Therapies
  - Musculoskeletal Cell and Gene Therapy Market by Indication
- Regional Market Summary
- Competitor Summary
Chapter 6: Cell and Gene Therapy Markets in Cardiovascular and Blood Disorders
- Overview
  - Cardiovascular Disease
  - Selected Blood Disorders
- Market Outlook
- Principal Products
  - Collategene
  - Hearticellgram
  - HeartSheet
  - Leqvio
  - Neovasculgen
  - Stempeucel
  - Zynteglo
  - Phase III Development
- Market Breakdown of Cell, Gene, and RNA Therapies
  - Cardiovascular and Blood Disorders Cell and Gene Therapy Market by Indication
- Regional Market Summary
- Competitor Summary
Chapter 7: Cell and Gene Therapy Markets in Dermatology
- Overview
- Market Outlook
- Principal Products
  - Adipocel
  - Apligraf
  - CureSkin
  - Dermagraft
  - Epicel
  - Grafix
  - Holoderm
  - Kaloderm
  - KeraHeal/KeraHeal-Allo
  - LaViv
  - Orcel
  - Quencell
  - RECELL
  - Rosmir
  - Stempeutics/Cutisera
  - StrataGraft
  - Stravix
  - TransCyte
  - Vyjuvek
- Trends in Research and Development
  - Phase III Development
- Market Breakdown of Cell and Gene Therapies
  - Dermatology Cell and Gene Therapy Market by Indication
- Regional Market Summary
- Competitor Summary
Chapter 8: Cell and Gene Therapy Markets in Other Conditions
- Overview
- Market Outlook
- Principal Products
  - Alofisel
  - Cupistem
  - Givlaari
  - Glybera
  - Holoclar
  - Luxturna
  - Oxlumo
  - Rethymic
  - Ryoncil/ Prochymal/ Temcell
  - Tryngolza
- Trends in Research and Development
- Market Breakdown of Cell and Gene Therapies
- Regional Market Summary
- Competitor Summary
Chapter 9: Cell and Gene Therapy Market Review
- Market Influences
  - Global Demographics
  - Cost Containment
- Cell and Gene Therapy and Viral Vector Shortages
- Global Market Summary
- Cell vs. Gene Therapy Markets
- Regional Market Overview
- North America
- Europe/European Union
- Other Countries
- Competitor Ranking in Cell and Gene Therapy Markets
Chapter 10: Market Participants
- Leading Influencers
- AlloSource
  - Company Summary
  - Products
- Alnylam Pharmaceuticals, Inc.
  - Company Summary
  - Products
- Amgen
  - Company Summary
  - Products
- AnGes Inc.
  - Company Summary
  - Products
- Anterogen Co Ltd.
  - Company Summary
  - Products
- Atara Biotherapeutics
  - Company Summary
  - Products
- BioCardia
  - Company Summary
  - Products
  - Projects in the pipeline using the CardiAMP system include:
  - Projects in the pipeline using the CardiALLO system include:
- Biogen, Inc.
  - Company Summary
  - Products
- BioMarin Pharmaceuticals
  - Company Summary
  - Products
- bluebird bio, Inc.
  - Company Summary
  - Products
- BrainStorm Cell Therapeutics
  - Company Summary
  - Products
- Bristol-Myers Squibb
  - Company Summary
  - Products
- Candel Therapeutics
  - Company Summary
  - Products
  - In the pipeline, the company offers:
- Castle Creek Biosciences
  - Company Summary
  - Products
- Celyad Oncology
  - Company Summary
  - Products
- Cook Myosite, Inc
  - Company Summary
  - Products
- Dendreon Pharmaceuticals (Sanpower)
  - Company Summary
  - Products
- Ferring Pharmaceuticals
  - Company Summary
  - Products
- Gamida Cell Ltd.
  - Company Summary
  - Products
- GenSight Biologics S.A.
  - Company Summary
  - Products
- Gilead Sciences, Inc.
  - Company Summary
  - Products
  - Other selected indications in the pipeline include:
- Gradalis, Inc
  - Company Summary
  - Products
- Helixmith
  - Company Summary
  - Products
- Inovio Pharmaceuticals, Inc.
  - Company Summary
  - Products in the Pipeline
- Medeor Therapeutics
  - Company Summary
  - Products
- MEDIPOST Co, Ltd.
  - Company Summary
  - Products
- MeiraGTx
  - Company Summary
  - Products
- Mesoblast Ltd.
  - Company Summary
  - Products
- Northwest Biotherapeutics, Inc.
  - Company Summary
  - Products
- Novartis AG
  - Company Summary
  - Products
  - Other Current Projects
- NuVasive Biologics
  - Company Summary
  - Products
- Orchard Therapeutics
  - Company Summary
  - Products
- Organogenesis
  - Company Summary
  - Products
- Orthofix
  - Company Summary
  - Products
- Osiris Therapeutics, Inc. (Smith & Nephew)
  - Company Summary
  - Products
- Pharmicell
  - Company Summary
  - Products
- Pluristem Therapeutics, Inc.
  - Company Summary
  - Products
- Sangamo Therapeutics
  - Company Summary
  - Products
- Sanofi
  - Company Summary
- Sarepta Therapeutics
  - Company Summary
  - Products
- Sotio a.s.
  - Company Summary
  - Products
- Spark Therapeutics
  - Company Summary
  - Products
  - Pipeline Projects
- uniQure N.V.
  - Company Summary
  - Products
- Vericel Corporation
  - Company Summary
  - Products